Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study - Wikidata - wikimedia - TriplyDB

Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study

Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study

http://www.wikidata.org/entity/Q57218116

about

Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study Phosphate binders in chronic kidney disease: a systematic review of recent data.Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection Management of hyperphosphataemia in chronic kidney disease-challenges and solutions Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.The role of phosphate in kidney disease.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Potassium supplementation and long-term outcomes in chronic peritoneal dialysis patients with end-stage renal disease: a propensity score matching study.The effect of omega-3 on serum lipid profile in hemodialysis patients Gastrointestinal complications induced by sevelamer crystals.Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.

P2860

Q28535870-CF2DAE96-EA2D-4A3F-ADD4-4E46B1F0C820 Q31039292-B0FF44F2-05E8-41AC-A4A0-34ACD8F225DE Q34430215-27C35ACE-CB42-48AB-8146-842ACF47385C Q35608435-2AD61997-243F-45B1-AC26-7108A3D8F0C4 Q35967669-DD891197-4C36-4FFA-8785-FF6F3D2BA150 Q38210438-6D40D82F-DD8B-449D-9375-FE9A91C5B8EF Q38231646-0F1FE5CA-3F68-4997-B4AB-508AE410BB7E Q38793054-EA8AB5B2-3655-47B1-9194-6555DB8CDC5C Q39220825-88F2FB15-3158-46F0-BB47-98D8D2E7FCB3 Q40521456-736D5D5B-E0C9-43B9-BFE0-68F81A11DDE4 Q41300518-95A487BE-2D7D-4A6F-86DE-2C3730A64B9A Q41510628-116EEE34-FBD8-405A-B58C-0AECCF04FF2C Q49846193-FA99FBA4-A4B3-49CC-B147-936E5A2EAECE

P2860

Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study

http://www.wikidata.org/entity/Q57218116

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2012

@uk

name

Effects of sevelamer hydrochlo ...... ty-matched observational study

@en

Effects of sevelamer hydrochlo ...... ty-matched observational study

@nl

type

label

Effects of sevelamer hydrochlo ...... ty-matched observational study

@en

Effects of sevelamer hydrochlo ...... ty-matched observational study

@nl

prefLabel

Effects of sevelamer hydrochlo ...... ty-matched observational study

@en

Effects of sevelamer hydrochlo ...... ty-matched observational study

@nl

P1433

Q57218116-51AA08E6-CE97-4C0F-A5C6-E9D091B7F902

P1476

Q57218116-156ACE93-68E3-4F3F-B03E-6376C3BD5390

P2093

Q57218116-3B1A62CA-99D3-4A83-AD66-F137A30FA2E6

Q57218116-5D0B3553-5F7B-4DAD-B154-85157498DEA9

Q57218116-78B138E0-13F2-4226-8FB3-66AEBB1D728F

Q57218116-7B039CEC-53A2-4B26-BD76-61AB809D1E95

Q57218116-83BC615D-9BEA-4BB5-A88C-5DDA9EA7C06F

Q57218116-8C4679F3-8FA1-49BA-9FC5-3B57576ACA7E

Q57218116-9AFAF4D1-0DDD-463D-9D45-146C52751771

Q57218116-A02FBDCF-7AE4-47A9-8EFE-B5D96E6FE307

Q57218116-A0A58A99-4C31-4B31-836C-1F8B0D003C5E

Q57218116-B22F1366-268A-458E-8CA7-AFFBD9A44C90

P2860

Q57218116-0E73131D-2071-4F79-9832-5F0AC07E3511

Q57218116-123D9798-EB67-4284-BAAA-A01FE6EAAACB

Q57218116-1526EC65-AC47-4D6C-8028-0225B7819941

Q57218116-1B168680-CC34-4935-83E6-4EB1731BDFC0

Q57218116-1B7F7F95-925C-4C38-AA84-0A7A35519556

Q57218116-3CC14DA2-6D57-414A-95BE-EC145EC5FA74

Q57218116-47C9FC91-C61A-4C77-8C68-5217E71EA846

Q57218116-60558F80-ACB0-41F3-83E6-F2AC52EBE912

Q57218116-7F6A0513-62E7-4498-B374-AF2BA682AFF3

Q57218116-9DBE5F36-7205-4003-A0C5-7E7590536C78

P2888

Q57218116-859C4B10-0B3E-4D08-9AC0-8D947FB93D06

P304

Q57218116-333DD15E-9C93-4C41-B303-39431B3B9B63

P31

Q57218116-7955BBB9-B2D4-4682-B6FA-80F0D61F44C5

P356

Q57218116-1C36DF57-7F44-453C-A2F7-D449FBA20F6E

P407

Q57218116-84D6CEFF-635B-4E35-BC4F-501171964CFC

P433

Q57218116-F190A608-8021-4478-A987-87BC0B18F30E

P478

Q57218116-4B327725-D72A-400B-9A08-6624DDFB0F40

P577

Q57218116-0BBB6C18-4314-487A-A2D0-39380F2B49C5

P698

Q57218116-87E923B5-4E52-4414-ACD1-3E53D0E2D38C

P356

S10157-012-0640-4

P1433

Clinical and experimental nephrology

P1476

Effects of sevelamer hydrochlo ...... ty-matched observational study

@en

P2093

Junichi Ishigami

http://www.w3.org/2001/XMLSchema#string

Masato Tajima

http://www.w3.org/2001/XMLSchema#string

Michio Kuwahara

http://www.w3.org/2001/XMLSchema#string

Satomi Shikuma

http://www.w3.org/2001/XMLSchema#string

Sei Sasaki

http://www.w3.org/2001/XMLSchema#string

Shigeru Takada

http://www.w3.org/2001/XMLSchema#string

Soichiro Iimori

http://www.w3.org/2001/XMLSchema#string

Tamaki Kuyama

http://www.w3.org/2001/XMLSchema#string

Tomokazu Okado

http://www.w3.org/2001/XMLSchema#string

Tomoki Asai

http://www.w3.org/2001/XMLSchema#string

P2860

Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Pathogenesis of vascular calcification in dialysis patients.

Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.

Evidence-based statin prescription for cardiovascular protection in renal impairment.

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study.

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

P2888

s10157-012-0640-4

P304

930-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10157-012-0640-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22581064

http://www.w3.org/2001/XMLSchema#string